Cargando…

Treatment of macular edema due to retinal vein occlusions

Retinal vein occlusion (RVO) is a prevalent retinal vascular disease, second only to diabetic retinopathy. Previously there was no treatment for central retinal vein occlusion (CRVO) and patients were simply observed for the development of severe complications, generally resulting in poor visual out...

Descripción completa

Detalles Bibliográficos
Autores principales: Channa, Roomasa, Smith, Michael, Campochiaro, Peter A
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104801/
https://www.ncbi.nlm.nih.gov/pubmed/21629578
http://dx.doi.org/10.2147/OPTH.S7632
_version_ 1782204643071229952
author Channa, Roomasa
Smith, Michael
Campochiaro, Peter A
author_facet Channa, Roomasa
Smith, Michael
Campochiaro, Peter A
author_sort Channa, Roomasa
collection PubMed
description Retinal vein occlusion (RVO) is a prevalent retinal vascular disease, second only to diabetic retinopathy. Previously there was no treatment for central retinal vein occlusion (CRVO) and patients were simply observed for the development of severe complications, generally resulting in poor visual outcomes. The only treatment for branch vein occlusion (BRVO) was grid laser photocoagulation, which reduces edema very slowly and provides benefit in some, but not all patients. Within the past year, clinical trials have demonstrated the effects of three new pharmacologic treatments, ranibizumab, triamcinolone acetonide, and dexamethasone implants. The benefit/risk ratio is best for intraocular injections of ranibizumab, making this first-line therapy for most patients with CRVO or BRVO, while intraocular steroids are likely to play adjunctive roles. Standard care for patients with RVO has changed and will continue to evolve as results with other new agents are revealed.
format Text
id pubmed-3104801
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31048012011-05-31 Treatment of macular edema due to retinal vein occlusions Channa, Roomasa Smith, Michael Campochiaro, Peter A Clin Ophthalmol Review Retinal vein occlusion (RVO) is a prevalent retinal vascular disease, second only to diabetic retinopathy. Previously there was no treatment for central retinal vein occlusion (CRVO) and patients were simply observed for the development of severe complications, generally resulting in poor visual outcomes. The only treatment for branch vein occlusion (BRVO) was grid laser photocoagulation, which reduces edema very slowly and provides benefit in some, but not all patients. Within the past year, clinical trials have demonstrated the effects of three new pharmacologic treatments, ranibizumab, triamcinolone acetonide, and dexamethasone implants. The benefit/risk ratio is best for intraocular injections of ranibizumab, making this first-line therapy for most patients with CRVO or BRVO, while intraocular steroids are likely to play adjunctive roles. Standard care for patients with RVO has changed and will continue to evolve as results with other new agents are revealed. Dove Medical Press 2011 2011-05-24 /pmc/articles/PMC3104801/ /pubmed/21629578 http://dx.doi.org/10.2147/OPTH.S7632 Text en © 2011 Channa et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Channa, Roomasa
Smith, Michael
Campochiaro, Peter A
Treatment of macular edema due to retinal vein occlusions
title Treatment of macular edema due to retinal vein occlusions
title_full Treatment of macular edema due to retinal vein occlusions
title_fullStr Treatment of macular edema due to retinal vein occlusions
title_full_unstemmed Treatment of macular edema due to retinal vein occlusions
title_short Treatment of macular edema due to retinal vein occlusions
title_sort treatment of macular edema due to retinal vein occlusions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104801/
https://www.ncbi.nlm.nih.gov/pubmed/21629578
http://dx.doi.org/10.2147/OPTH.S7632
work_keys_str_mv AT channaroomasa treatmentofmacularedemaduetoretinalveinocclusions
AT smithmichael treatmentofmacularedemaduetoretinalveinocclusions
AT campochiaropetera treatmentofmacularedemaduetoretinalveinocclusions